15-Hydroxyprostaglandin Dehydrogenase in Colorectal Mucosa as a Potential Biomarker for Predicting Colorectal Neoplasms

다국어 초록 (Multilingual Abstract)

15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is downregulated during the early stages of colorectal carcinogenesis. The aim of the present study was to investigate the potential role of 15-PGDH in normal-appearing colorectal mucosa as a biomarker for predicting colorectal neoplasms. We obtained paired tumor and normal tissues from the surgical specimens of 32 sporadic colorectal cancer patients. mRNA expression of 15-PGDH was measured using a quantitative real-time PCR assay. We evaluated the association between 15-PGDH mRNA expression in normal-appearing mucosa, the presence of synchronous adenoma, and the cumulative incidence of metachronous adenoma. The relative 15-PGDH expression of normal-appearing mucosa in patients with synchronous adenoma was significantly lower than in patients without synchronous adenoma (0.71 vs 1.00, P = 0.044). The patients in the lowest tertile of 15-PGDH expression in normalappearing mucosa were most likely to have synchronous adenoma (OR: 10.5, P = 0.024).
Patients with low 15-PGDH expression in normal-appearing mucosa also demonstrated more advanced stage colorectal cancer (P = 0.045). However, there was no significant difference in the cumulative incidence of metachronous adenoma according to 15-PGDH mRNA expression in normal-appearing mucosa (P = 0.333). Hence, 15-PGDH in normalappearing colorectal mucosa can be a useful biomarker of field effect for the prediction of sporadic synchronous neoplasms.

참고문헌 (Reference)

1 Smartt HJ, "β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells" 61 : 1306-1314, 2012

2 Tai HH, "Prostaglandin catabolizing enzymes" 68-69 : 483-493, 2002

3 Chan AT, "Primary prevention of colorectal cancer" 138 : 2029-2043, 2010

4 Belshaw NJ, "Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa" 31 : 1158-1163, 2010

5 Martin C, "Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas" 123 : 1770-1777, 2002

6 Cha YI, "NSAIDs and cancer prevention: targets downstream of COX-2" 58 : 239-252, 2007

7 Markowitz SD, "Molecular origins of cancer: molecular basis of colorectal cancer" 361 : 2449-2460, 2009

8 Thibodeau SN, "Microsatellite instability in cancer of the proximal colon" 260 : 816-819, 1993

9 Shen L, "MGMT promoter methylation and field defect in sporadic colorectal cancer" 97 : 1330-1338, 2005

10 Baytner S, "Immunohistochemical expression of mutant p53 oncogene in transitional mucosa adjacent to human colon cancer" 16 : 379-385, 1993

11 Chung SJ, "Five-year risk for advanced colorectal neoplasia after initial colonoscopy according to the baseline risk stratification: a prospective study in 2452 asymptomatic Koreans" 60 : 1537-1543, 2011

12 Jothy S, "Field effect of human colon carcinoma on normal mucosa: relevance of carcinoembryonic antigen expression" 17 : 58-64, 1996

13 Slaughter DP, "Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin" 6 : 963-968, 1953

14 Worthley DL, "DNA methylation within the normal colorectal mucosa is associated with pathwayspecific predisposition to cancer" 29 : 1653-1662, 2010

15 Gupta RA, "Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2" 1 : 11-21, 2001

16 Siegel R, "Cancer statistics, 2012" 62 : 10-29, 2012

17 정규원, "Cancer Statistics in Korea: Incidence, Mortality and Survival in 2005" 대한의학회 24 (24): 995-1003, 2009

18 Srivastava S, "Biomarkers for early detection of colon cancer" 7 : 1118-1126, 2001

19 Markowitz SD, "Aspirin and colon cancer: targeting prevention?" 356 : 2195-2198, 2007

20 Keku TO, "Apoptosis in normal rectal mucosa, baseline adenoma characteristics, and risk of future adenomas" 17 : 306-310, 2008

21 Martinez ME, "Adenoma characteristics as risk factors for recurrence of advanced adenomas" 120 : 1077-1083, 2001

22 Braakhuis BJ, "A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications" 63 : 1727-1730, 2003

23 Yan M, "15-hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers" 101 : 17468-17473, 2004

24 Myung SJ, "15-hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis" 103 : 12098-12102, 2006